Tilt Investment Management Holdings PBC Sells 861 Shares of Eli Lilly and Company (NYSE:LLY)

Tilt Investment Management Holdings PBC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 20.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,271 shares of the company’s stock after selling 861 shares during the period. Eli Lilly and Company comprises about 2.1% of Tilt Investment Management Holdings PBC’s portfolio, making the stock its 8th largest holding. Tilt Investment Management Holdings PBC’s holdings in Eli Lilly and Company were worth $1,907,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company during the fourth quarter valued at $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter worth about $27,000. Retirement Group LLC grew its position in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the last quarter. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth about $33,000. Finally, Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the third quarter worth about $35,000. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.8 %

LLY traded down $6.32 during midday trading on Thursday, hitting $744.45. 990,506 shares of the company’s stock traded hands, compared to its average volume of 3,057,192. The company has a market cap of $707.35 billion, a PE ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The stock’s fifty day simple moving average is $764.03 and its 200-day simple moving average is $657.67. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the firm posted $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on LLY. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.